EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The synthetic cannabinoid WIN 55,212-2 attenuates cognitive and motor deficits and reduces amyloid load in 5XFAD Alzheimer mice

Johanna E L Möller, Franziska W Schmitt, Daniel Günther, Alicia Stöver, Yvonne Bouter

Pharmacology Biochemistry and Behavior · 2025-02 · 247 · 173944

DOI: 10.1016/j.pbb.2024.173944 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Biochemistry and Behavior, 2025-02. Verfasst von Johanna E L Möller und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August-University, Goettingen, Germany. Hauptthemen laut MEDLINE: Benzoxazines, Naphthalenes, Morpholines, Alzheimer Disease. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Alzheimer's disease (AD) is characterized by cognitive decline, with pathological features including amyloid β (Aβ) plaques and inflammation. Despite recent approvals of anti-amyloid antibodies, there remains a need for disease-modifying and easily accessible therapies. The endocannabinoid system presents a promising target for AD treatment, as it regulates various processes implicated in AD pathogenesis. AIMS: This study assesses the effects of the synthetic cannabinoid WIN 55,212-2 on AD pathology and behavior deficits in aged 5XFAD mice, a well-established AD model. METHODS: Male 9-month-old 5XFAD mice received either 0.2 mg/kg WIN 55,212-2 or a vehicle solution for 42 days. Memory, anxiety, and motor tests were conducted at 10 months to identify potential changes in behavior and cognition following WIN 55,212-2 treatment. Additionally, the effects of prolonged WIN 55,212-2 treatment on Aβ pathology and neuroinflammation in the brain were quantified immunohistochemically. RESULTS: Therapeutic WIN 55,212-2 treatment improved the motor performance of 5XFAD mice on the rotarod and rescued memory deficits in the water maze. However, WIN 55,212-2 treatment did not significantly affect anxiety-like behavior in 5XFAD mice. Additionally, prolonged treatment with WIN 55,212-2 reduced Aβ plaque pathology and astrogliosis in the cortex and hippocampus. CONCLUSIONS: This study highlights the therapeutic potential of WIN 55,212-2 in AD by ameliorating cognitive and motor deficits and reducing neuropathology. These findings support a cannabinoid-based therapy as a promising strategy for AD treatment, with WIN 55,212-2 emerging as a potential candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzoxazinesNaphthalenesMorpholinesAlzheimer DiseaseAmyloid beta-PeptidesCognitionCannabinoidsAnimalsMaleMiceMice, TransgenicDisease Models, AnimalPlaque, AmyloidBrain

Stichwörter der Autor:innen

AbetaAlzheimerBehavior testingCannabisMedical marijuanaWIN 55,212-2

Substanzen

Benzoxazines(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanoneNaphthalenesMorpholinesAmyloid beta-PeptidesCannabinoids

Autor:innen und Institutionen

  • Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August-University, Goettingen, Germany.
  • Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August-University, Goettingen, Germany; Department of Nuclear Medicine, University Medical Center Göttingen, Goettingen, Germany. Electronic a…

Zitieren

APA

Möller, J. E. L., Schmitt, F. W., Günther, D., Stöver, A., & Bouter, Y. (2025). The synthetic cannabinoid WIN 55,212-2 attenuates cognitive and motor deficits and reduces amyloid load in 5XFAD Alzheimer mice. Pharmacology Biochemistry and Behavior, 247, 173944. https://doi.org/10.1016/j.pbb.2024.173944

Vancouver

Möller JEL, Schmitt FW, Günther D, Stöver A, Bouter Y. The synthetic cannabinoid WIN 55,212-2 attenuates cognitive and motor deficits and reduces amyloid load in 5XFAD Alzheimer mice. Pharmacology Biochemistry and Behavior. 2025;247:173944. doi:10.1016/j.pbb.2024.173944

BibTeX
@article{Mller2025,
  author = {Möller, Johanna E L and Schmitt, Franziska W and Günther, Daniel and Stöver, Alicia and Bouter, Yvonne},
  title = {The synthetic cannabinoid WIN 55,212-2 attenuates cognitive and motor deficits and reduces amyloid load in 5XFAD Alzheimer mice},
  journal = {Pharmacology Biochemistry and Behavior},
  year = {2025},
  volume = {247},
  pages = {173944},
  doi = {10.1016/j.pbb.2024.173944}
}
Kostenlos starten →